EcoR1 Capital

Director at Aktis Oncology · 10 reported transactions in 3 companies · latest trade Jan 12, 2026

Their record

Across their whole record, 1 purchase can be measured; 1 did better than the S&P 500 over the next 6 months.

Typical move +26.8%, S&P 500 +7.6% over the same days.


Aktis OncologyAKTS	Bought $2.6M · 144,443 shares	Jan 12, 2026	S&P 500 +10.1%thru Oct 26
Aktis OncologyAKTS	Bought $37.4M · 2,077,779 shares	Jan 12, 2026	S&P 500 +10.1%thru Oct 26
Adaptimmune TherapeuticsADAP	Sold $2.8M · 27,433,338 shares	Jul 30, 2025
Adaptimmune TherapeuticsADAP	Sold $272K · 2,687,460 shares	Jul 29, 2025
Adaptimmune TherapeuticsADAP	Sold $3.82M · 33,931,740 shares	Jul 28, 2025

Jan 12, 2026 · AKTS

$2.6M

S&P 500 +10.1%thru Oct 26

Jan 12, 2026 · AKTS

$37.4M

S&P 500 +10.1%thru Oct 26

Jul 30, 2025 · ADAP

$2.8M

Jul 29, 2025 · ADAP

$272K

Jul 28, 2025 · ADAP

$3.82M

10 transactionsPro adds every trade with how it did, their holdings and the money-flow chartPro is $29 a month

Built from their public trade reports and market prices: past moves, not predictions or advice.

Director at Aktis Oncology · 10 reported transactions in 3 companies · latest trade Jan 12, 2026

Across their whole record, 1 purchase can be measured; 1 did better than the S&P 500 over the next 6 months.

Typical move +26.8%, S&P 500 +7.6% over the same days.


Aktis OncologyAKTS	Bought $2.6M · 144,443 shares	Jan 12, 2026	S&P 500 +10.1%thru Oct 26
Aktis OncologyAKTS	Bought $37.4M · 2,077,779 shares	Jan 12, 2026	S&P 500 +10.1%thru Oct 26
Adaptimmune TherapeuticsADAP	Sold $2.8M · 27,433,338 shares	Jul 30, 2025
Adaptimmune TherapeuticsADAP	Sold $272K · 2,687,460 shares	Jul 29, 2025
Adaptimmune TherapeuticsADAP	Sold $3.82M · 33,931,740 shares	Jul 28, 2025